UbiVac Secures $185K Investment to Accelerate Breakthrough Cancer Immunotherapies

UbiVac, a pioneering clinical-stage biotech company dedicated to revolutionizing cancer treatment through innovative immunotherapies, is proud to announce a recent funding round that raised $185,000. This new capital injection will accelerate their ambitious research and development initiatives, particularly focusing on the further development and clinical translation of their flagship agent, DPV-001. As UbiVac continues to build on its impressive scientific foundation—highlighted by high-impact publications revealing a previously unknown class of shared non-mutated cancer neoantigens and groundbreaking preclinical models demonstrating cross-protective cancer immunity—this funding will be strategically deployed to enhance ongoing clinical trials and bolster manufacturing capabilities. With an extensive track record in the discovery, development, and delivery of therapeutic immune activators, vaccines, and cellular immunotherapies, UbiVac is uniquely positioned to address some of the most challenging forms of cancer. The company’s commitment is evident in its rigorous NCI-funded phase I/II adjuvant trial of DPV-001, which successfully met its endpoints by affirming safety, optimizing drug formulation, and demonstrating robust proof-of-concept. Moreover, the promising collaboration with Providence Cancer Institute and Incyte on a first-in-human immunotherapy trial targeting advanced HNSCC marks a significant milestone in UbiVac’s clinical journey. The newly secured funding will further power UbiVac's exploration into off-the-shelf Universal Cancer Vaccines and expand its pipeline of innovative cellular therapies. With over 55 years of cumulative expertise from its leadership team, UbiVac continues to propel forward, driving advancements that could redefine cancer treatment paradigms and offer new hope for patients worldwide.